A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

Project: Other project

Project Details

StatusActive
Effective start/end date9/17/209/16/25

Funding

  • Mitsubishi Tanabe Pharma: $49,455.39